NIMML Institute
The NIMML Institute is a 501(c)(3) non-profit public charity foundation employing a transdisciplinary, team-science approach to precision medicine at the intersection of immunology, inflammation, and metabolism. They focus on solving societal problems by integrating expertise from immunologists, computational biologists, toxicologists, modelers, translational researchers, and molecular biologists. NIMML views the immune system as a dynamic, interacting system and applies advanced computational methods to understand its complexity, accelerating the discovery of novel therapeutic pathways for autoimmune, infectious, and chronic inflammatory diseases. Their research spans in silico, in vitro, mechanistic, translational, and clinical trials (Phase 1-4), pioneering platforms that integrate high-throughput computational and experimental immunology with systems biology approaches. NIMML leverages AI-powered platforms like TITAN-X to accelerate therapeutic development, as demonstrated by their work on Omilancor for ulcerative colitis and NIM-1324 for systemic lupus erythematosus.
NIMML Institute
The NIMML Institute is a 501(c)(3) non-profit public charity foundation employing a transdisciplinary, team-science approach to precision medicine at the intersection of immunology, inflammation, and metabolism. They focus on solving societal problems by integrating expertise from immunologists, computational biologists, toxicologists, modelers, translational researchers, and molecular biologists. NIMML views the immune system as a dynamic, interacting system and applies advanced computational methods to understand its complexity, accelerating the discovery of novel therapeutic pathways for autoimmune, infectious, and chronic inflammatory diseases. Their research spans in silico, in vitro, mechanistic, translational, and clinical trials (Phase 1-4), pioneering platforms that integrate high-throughput computational and experimental immunology with systems biology approaches. NIMML leverages AI-powered platforms like TITAN-X to accelerate therapeutic development, as demonstrated by their work on Omilancor for ulcerative colitis and NIM-1324 for systemic lupus erythematosus.